학술논문
Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer
Document Type
Article
Author
Source
In The Lancet Regional Health - Western Pacific July 2024 48
Subject
Language
ISSN
2666-6065